WINTHER
WINTHERapeutics: development of a systems biology method to predict efficacy of cancer drugs to optimize individualized therapeutic decision and improve clinical outcome for cancer patients
| Coordinatore | INSTITUT GUSTAVE ROUSSY
Organization address
address: Rue Camille Desmoulins 39 contact info |
| Nazionalità Coordinatore | France [FR] |
| Totale costo | 4˙229˙837 € |
| EC contributo | 2˙998˙355 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2012-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-03-01 - 2015-02-28 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
INSTITUT GUSTAVE ROUSSY
Organization address
address: Rue Camille Desmoulins 39 contact info |
FR (VILLEJUIF) | coordinator | 991˙102.00 |
| 2 |
ARIANA PHARMACEUTICALS SA
Organization address
address: RUE DU DOCTEUR FINLAY 28 contact info |
FR (PARIS CEDEX) | participant | 440˙496.00 |
| 3 |
FOUNDATION MEDICINE INC
Organization address
address: KENDALL SQUARE 1 SUITE B3501 contact info |
US (CAMBRIDGE) | participant | 368˙000.00 |
| 4 |
MEDICAL RESEARCH INFRASTRUCTURE DEVELOPMENT AND HEALTH SERVICES FUND BY THE SHEBA MEDICAL CENTER
Organization address
address: TEL HASHOMER SHEBA MEDICAL CENTER contact info |
IL (RAMAT GAN) | participant | 315˙813.00 |
| 5 |
BEN-GURION UNIVERSITY OF THE NEGEV
Organization address
address: Office of the President - Main Campus contact info |
IL (BEER SHEVA) | participant | 306˙000.00 |
| 6 |
WORLDWIDE INNOVATIVE NETWORK ASSOCIATION
Organization address
address: RUE EDOUARD VAILLANT 114 contact info |
FR (VILLEJUIF) | participant | 208˙620.00 |
| 7 |
Jewish General Hospital
Organization address
address: 3755 CHEMIN COTE SAINTE CATHERINE contact info |
CA (MONTREAL QC) | participant | 164˙794.00 |
| 8 |
FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON
Organization address
city: Barcelona contact info |
ES (Barcelona) | participant | 147˙952.00 |
| 9 |
THE UNIVERSITY OF TEXAS SYSTEM
Organization address
address: COLORADO STREET 601 contact info |
US (AUSTIN) | participant | 55˙578.00 |
| 10 |
STICHTING SAGE BIONETWORKS EU
Organization address
address: NOORDERAKERWEG 271 B contact info |
NL (AMSTERDAM) | participant | 0.00 |
| 11 |
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Organization address
address: "FRANKLIN STREET 1111, 12 FLOOR" contact info |
US (OAKLAND CA) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Relevance: WINTHER project focuses on the development and validation, in 24 months, of industry supported new tools and computational methods, to predict efficacy of drugs in cancer patients Current medical needs: Selection of cancer targeted therapies based on molecular abnormalities (mutations /amplifications/ translocations) benefit today only to 10-40% of patients. For the remaining majority, therapeutic decision is still based according to decade-old protocols with limited efficacy. Drug development depends on efficiency of clinical trials, with a staggering 95% failure rate
The objective: WINTHER proposes a fundamental change in trial design, through: 1. investigation of the tumour simultaneously with the normal matched tissue 2. development of a comprehensive database and genomic based algorithms and computational tools to predict the efficacy of drugs at individual level, in all patients, irrespective of cancer type 3. increase efficacy of therapeutics and clinical outcome,
Impact: Optimization of the portfolio of existing drugs and new compounds in clinical trials by matching the right drug to the right patient. In particular, it permits to avoid use of expensive drugs for patients that would not benefit from such treatments. WINTHER will made available to community as a clinically validated industry tool (website, database and algorithms) to assist clinicians in the analysis of genomic information based on the comparison of tumour and matched normal tissue and to increase the number of the patients to benefit from individualized rational selection of therapies.'
Altri progetti dello stesso programma (FP7-HEALTH)
ESMART (2014)
Randomised controlled trial to evaluate electronic Symptom Management using the Advanced Symptom Management System (ASyMS) Remote Technology for patients with cancers
Read MoreDALI (2010)
Vitamin D And LIfestyle Intervention for Gestational Diabetes Mellitus (GDM) Prevention
Read More